Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 26, 2006

Leader Ventures Closes $300-M Fund

  • Leader Ventures launched a fund to provide $300 million in debt and equity to private and public companies. Leader primarily invests in venture-backed companies, including those in the life sciences sectors.

    “We are delighted to be investors in Leader's new fund,” says Richard Harris, manager of M.A.R.S. Lattner, LP, an Atlanta-based family office. “With a solid track record and over 37 years of investing and lending experience, the Leader team has proven their ability to meet the needs of growing companies and deliver top-quartile returns to investors.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »